Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients

There is consensus in the oncology community that there is a large need for personalized cancer treatment decisions as patients suffer from large-scale overtreatment. Up to 90% of patients receiving adjuvant chemotherapy have no effect, many suffer severe side effects.

DoMore Diagnostics (DoMore Dx) delivers pioneering diagnostics software that enables personalized cancer treatment in a simple and cost-efficient way.

We provide deep learning algorithms applied to cancer tissue whole slide images (WSI) in the adjuvant chemotherapy setting. With end-to-end deep learning we have taken a completely new approach to this challenge. Our test can be run in local labs with digital pathology equipment and does not consume any tissue.

DoMore Dx is personalized medicine made simple.In CRC, our test can stratify patients into low, intermediate, or high risk with a hazard ratio >10.

This information can be used to take up to 250,000 patients out of chemotherapy and save 4 billion EUR globally every year.